Figure

Graphic file number 0 named letter~2.jpg with height 87 p and width 86 p Left aligned

UTAH STATE SENATE
UTAH STATE CAPITOL COMPLEX * 320 STATE CAPITOL

P.O. BOX 145115 * SALT LAKE CITY, UTAH 84114-5115 * (801) 538-1035

        February 20, 2013

Mr. President:

    The Health and Human Services Committee reports a favorable recommendation on S.B. 78, PHARMACY ACT AMENDMENTS, by Senator J. S. Adams, with the following amendments:

1.    Page 17, Lines 501 through 509 :    

             501          (7) A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar
             502      product for a prescribed biological product shall

  communicate the substitution to the purchaser. The interchangeable biosimilar product container shall be labeled with the name of the interchangeable biosimilar product dispensed, and the pharmacist, pharmacy intern, or pharmacy technician shall indicate on the file copy of the prescription both the name of the prescribed biological product and the name of the interchangeable biosimilar product dispensed in its place.            {   :

             503          (a) communicate the substitution to the purchaser;
             504          (b) ensure that the interchangeable product container is labeled with the name and the
             505      manufacturer of the interchangeable biosimilar product dispensed; and
             506          (c) indicate on the file copy of the prescription:
             507          (i) the name and the manufacturer of the prescribed biological product; and
             508          (ii) the name and the manufacturer of the interchangeable biosimilar product dispensed
             509      in place of the prescribed biological product.   }

2.    Page 17, Lines 510 through 516 :    

             510          (8) A pharmacist or pharmacy intern who substitutes an interchangeable biosimilar
             511      product for a prescribed biological product shall:
             512          (a) notify the prescriber in writing
  , by fax, telephone, or electronic transmission       of the substitution, as soon as practicable, but not

             513      later than three business days after dispensing the interchangeable biosimilar product in place
             514      of the prescribed biological product; and
             515          (b) include the name and manufacturer of the interchangeable biosimilar product
             516      substituted.

3.    Page 17, Lines 517 through 521 :    

             517          
{   (9) The pharmacist or pharmacy intern shall:

             518          (a) retain a written record of the substitution for at least five years; and
             519          (b) include the name and manufacturer of the interchangeable product substituted.   }
             520          
{   (10)   }        (9)       A licensed medical practitioner who fails to specify that no substitution is

             521      authorized does not constitute evidence of negligence.

        Respectfully,

        Evan J. Vickers
        Committee Chair

Voting: 3-1-1
3 SB0078.SC1.wpd markandrews/MDA AKJ/MDA 2/20/13 6:02 pm

Bill Number
Action Class
Action Code

*SB0078*
*S*
*SCRAMD*

 SB0078
S
SCRAMD